{"analyses":[{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"99","ciUpperLimit":"0.80","estimateComment":"Stratified Cox Proportional Hazards model. A hazard ratio \\< 1 favours Dato-DXd.","groupDescription":"Dato-DXd vs ICC","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"95% Confidence Interval 2-Sided\n\n0.52 to 0.76","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.63","statisticalComment":"Adjusted for stratification factors","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"7.4","value":"6.9"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"5.5","value":"4.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"365"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"description":"PFS is defined as time from randomization until progression per RECIST 1.1, as assessed by BICR, or death due to any cause. The analysis will include all randomized participants as randomized regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy, or clinically progresses prior to RECIST 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Arm 1: Dato-DXd","id":"OG000","title":"Dato-DXd"},{"description":"Arm 2: ICC (Capecitabine or Gemcitabine or Eribulin mesylate or Vinorelbine)","id":"OG001","title":"Investigator's Choice of Chemotherapy (ICC)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months","title":"Progression-Free Survival","type":"PRIMARY","unitOfMeasure":"Months"}